ATI RN
ATI Pharmacology Proctored Exam 2019
1. A healthcare provider in an emergency unit is reviewing the medical record of a client who is being evaluated for angle-closure glaucoma. Which of the following findings are indicative of this condition?
- A. Insidious onset of painless loss of vision
- B. Gradual reduction in peripheral vision
- C. Severe pain around the eyes
- D. Intraocular pressure of 12mm Hg
Correct answer: C
Rationale: Severe pain around the eyes that radiates over the face is a characteristic symptom of acute angle-closure glaucoma. This intense pain is typically accompanied by other symptoms such as blurred vision, halos around lights, redness in the eye, and sometimes nausea and vomiting. The acute rise in intraocular pressure leads to these symptoms, indicating a medical emergency that requires immediate attention to prevent vision loss. Choices A, B, and D are incorrect. Insidious onset of painless loss of vision is more suggestive of conditions like age-related macular degeneration or diabetic retinopathy. Gradual reduction in peripheral vision is commonly seen in conditions like open-angle glaucoma. An intraocular pressure of 12mm Hg is within the normal range and not indicative of the acute rise seen in angle-closure glaucoma.
2. A client is starting therapy with docetaxel. Which of the following findings should the nurse instruct the client to report?
- A. Flushing
- B. Dyspnea
- C. Hyperglycemia
- D. Tinnitus
Correct answer: B
Rationale: The correct answer is B: Dyspnea. The nurse should instruct the client to report dyspnea because it can indicate pulmonary toxicity, a severe adverse effect of docetaxel. Dyspnea may suggest a potential serious condition that needs prompt evaluation and intervention to prevent complications. Flushing (choice A) is more commonly associated with other medications or conditions and is not a common side effect of docetaxel. Hyperglycemia (choice C) and tinnitus (choice D) are also not typically associated with docetaxel therapy and are not priority findings that the nurse should instruct the client to report.
3. When starting therapy with doxorubicin, which of the following findings should the nurse instruct the client to report?
- A. Hair loss
- B. Fatigue
- C. Sore throat
- D. Red urine
Correct answer: C
Rationale: The nurse should instruct the client to report a sore throat because it can indicate an infection due to the immunosuppressive effects of doxorubicin. Doxorubicin is known to suppress the immune system, making patients more susceptible to infections. Monitoring and reporting early signs of infection, such as a sore throat, are essential to prevent complications. Hair loss and fatigue are common side effects of doxorubicin but do not typically indicate immediate concerns for infection. Red urine is a known side effect of doxorubicin but is not a priority over potentially serious infections that can arise.
4. A client with Preeclampsia is receiving Magnesium Sulfate IV continuous infusion. Which of the following findings should the nurse report to the provider?
- A. 2+ deep tendon reflexes
- B. 2+ pedal edema
- C. 24 mL/hr urinary output
- D. Respirations 12/min
Correct answer: C
Rationale: In a client receiving Magnesium Sulfate IV continuous infusion for Preeclampsia, a urinary output less than 25 to 30 mL/hr is indicative of magnesium sulfate toxicity and should be promptly reported to the provider for further evaluation and management. Therefore, the correct answer is C. Option A, 2+ deep tendon reflexes, are expected findings in a client receiving magnesium sulfate and do not require immediate reporting. Option B, 2+ pedal edema, is a common symptom of preeclampsia and typically does not require immediate intervention. Option D, respirations 12/min, are within the normal range and do not indicate an immediate need for reporting to the provider.
5. A client is receiving treatment with bevacizumab. Which of the following findings should the nurse monitor?
- A. Hypertension
- B. Hypokalemia
- C. Hyperglycemia
- D. Hypocalcemia
Correct answer: A
Rationale: Correct Answer: A. Bevacizumab is known to cause hypertension as a common adverse effect. The nurse should closely monitor the client's blood pressure to detect and manage this potential side effect promptly. Choice B, hypokalemia, is not typically associated with bevacizumab treatment. Choice C, hyperglycemia, is not a common adverse effect of bevacizumab. Choice D, hypocalcemia, is not a recognized side effect of bevacizumab.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access